An Open-Label, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 in Combination With Toripalimab in Patients With Advanced NEN and Other Solid Tumors
Latest Information Update: 07 May 2025
At a glance
- Drugs Porustobart (Primary) ; Toripalimab (Primary)
- Indications Carcinoma; Neuroendocrine tumours; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Harbour BioMed
Most Recent Events
- 27 Apr 2025 Planned End Date changed from 3 Jun 2024 to 30 Jun 2026.
- 27 Apr 2025 Planned primary completion date changed from 17 Oct 2023 to 30 Sep 2025.
- 27 Apr 2025 Status changed from recruiting to active, no longer recruiting.